GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Er-Kang Pharmaceutical Co Ltd (SZSE:300267) » Definitions » Revenue

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Revenue : ¥1,512 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Er-Kang Pharmaceutical Co Revenue?

Hunan Er-Kang Pharmaceutical Co's revenue for the three months ended in Mar. 2024 was ¥276 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥1,512 Mil. Hunan Er-Kang Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥0.13. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥0.73.

Warning Sign:

Hunan Er-Kang Pharmaceutical Co Ltd revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Hunan Er-Kang Pharmaceutical Co was -24.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -9.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -7.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Hunan Er-Kang Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 60.60% per year. The lowest was -15.90% per year. And the median was 21.70% per year.


Hunan Er-Kang Pharmaceutical Co Revenue Historical Data

The historical data trend for Hunan Er-Kang Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Er-Kang Pharmaceutical Co Revenue Chart

Hunan Er-Kang Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,744.34 2,382.28 2,235.30 1,870.54 1,783.12

Hunan Er-Kang Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 546.93 503.24 395.21 337.75 275.79

Competitive Comparison of Hunan Er-Kang Pharmaceutical Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Er-Kang Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Er-Kang Pharmaceutical Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Er-Kang Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where Hunan Er-Kang Pharmaceutical Co's Revenue falls into.



Hunan Er-Kang Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,512 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hunan Er-Kang Pharmaceutical Co  (SZSE:300267) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Hunan Er-Kang Pharmaceutical Co Revenue Related Terms

Thank you for viewing the detailed overview of Hunan Er-Kang Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Business Description

Traded in Other Exchanges
N/A
Address
Kangping Road 167, National Economic and Technological Development Zone, Liuyang Changsha, Hunan, CHN, 410331
Hunan Er-Kang Pharmaceutical Co Ltd develops, produces and sells pharmaceutical products in China. The company's main products include pharmaceutical excipients and antibiotics. It offers pharmaceutical excipients, APIs and finished drug products. The pharmaceutical excipients include products such as glycerol, ethanol pharmaceutically, acceptable propylene glycol, sodium hydroxide, and pharmaceutically acceptable sugar. The company's finished drugs primarily include sulbenicillin sodium for injection and compound liquorice tablets. Its APIs include glycerin, dilute hydrochloric acid, dihydroxypropyl theophylline, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. Geographically, all the activities are carried out through China.

Hunan Er-Kang Pharmaceutical Co (SZSE:300267) Headlines

No Headlines